[go: up one dir, main page]

DE69840195D1 - Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 - Google Patents

Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1

Info

Publication number
DE69840195D1
DE69840195D1 DE69840195T DE69840195T DE69840195D1 DE 69840195 D1 DE69840195 D1 DE 69840195D1 DE 69840195 T DE69840195 T DE 69840195T DE 69840195 T DE69840195 T DE 69840195T DE 69840195 D1 DE69840195 D1 DE 69840195D1
Authority
DE
Germany
Prior art keywords
amino acids
epitope
hiv
compositions
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840195T
Other languages
English (en)
Inventor
Gideon Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thymon LLC
Original Assignee
Thymon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thymon LLC filed Critical Thymon LLC
Application granted granted Critical
Publication of DE69840195D1 publication Critical patent/DE69840195D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69840195T 1997-07-11 1998-07-10 Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 Expired - Lifetime DE69840195D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/893,853 US5891994A (en) 1997-07-11 1997-07-11 Methods and compositions for impairing multiplication of HIV-1
PCT/US1998/014332 WO1999002185A1 (en) 1997-07-11 1998-07-10 Methods and compositions for impairing multiplication of hiv-1

Publications (1)

Publication Number Publication Date
DE69840195D1 true DE69840195D1 (de) 2008-12-18

Family

ID=25402225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840195T Expired - Lifetime DE69840195D1 (de) 1997-07-11 1998-07-10 Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1

Country Status (9)

Country Link
US (6) US5891994A (de)
EP (1) EP0994724B1 (de)
JP (1) JP4278293B2 (de)
AT (1) ATE413189T1 (de)
AU (1) AU745012C (de)
CA (1) CA2295691C (de)
DE (1) DE69840195D1 (de)
ES (1) ES2317668T3 (de)
WO (1) WO1999002185A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG71046A1 (en) * 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20010008627A1 (en) * 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2000078969A1 (en) * 1999-06-21 2000-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv tat peptides and multiple peptide conjugate system
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
IL161584A0 (en) 2001-11-21 2004-09-27 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7553926B2 (en) * 2002-04-23 2009-06-30 Andrea Savarino Compositions containing anti-HIV peptides and methods for use
WO2004056316A2 (en) * 2002-12-18 2004-07-08 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
WO2005062871A2 (en) * 2003-12-19 2005-07-14 University Of Maryland Biotechnology Institute Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US8178649B2 (en) * 2004-12-07 2012-05-15 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
CN101213212A (zh) * 2005-02-15 2008-07-02 西蒙有限公司 削弱hiv-1增殖的方法和组合物
US20080280305A1 (en) * 2005-02-15 2008-11-13 Thymon, Llc Assays for Detecting Hiv-1 Tat Protein in Hiv-1 Infection
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
US8231880B2 (en) 2007-11-28 2012-07-31 The Trustess Of The University Of Pennsylvania Simian subfamily C adenoviruses SAdV-40, -31, and -34 and uses thereof
SI2220241T1 (sl) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010051367A1 (en) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
DK2411043T3 (da) 2009-03-23 2013-10-21 Pin Pharma Inc Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
AU2013262626B2 (en) 2012-05-18 2018-11-29 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
CN104981479B (zh) * 2012-12-06 2021-06-01 品诺制药公司 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP3052127A1 (de) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunstimulierende hiv-tat-derivierende polypeptide zur verwendung bei der krebsbehandlung
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
SG11201609207SA (en) 2014-05-13 2016-12-29 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
CN119072330A (zh) 2022-03-14 2024-12-03 世代生物公司 异源初免加强疫苗组合物和使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4531167A (en) * 1983-08-25 1985-07-23 Pioneer Research, Inc. Servowriter system for magnetic disc drives
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US6858712B1 (en) * 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5801056A (en) * 1985-05-24 1998-09-01 Dana-Farber Cancer Institute Nucleic acid encoding HIV-1 tat protein
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
PT83682B (en) * 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
CS256960B1 (en) * 1985-11-16 1988-04-15 Viktor Krchnak Peptides with properties of antigenic determinants and method of their production
US4812929A (en) * 1985-11-19 1989-03-14 Rodime Plc Head positioning mechanism for rotating disk data storage system
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5306614A (en) * 1986-01-22 1994-04-26 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2)
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5476765A (en) * 1987-01-09 1995-12-19 United Biomedical, Inc. Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
GB8808892D0 (en) * 1988-04-15 1988-05-18 British Bio Technology Gene synthesis
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
DE69028412T2 (de) * 1989-12-21 1997-03-27 Univ Johns Hopkins Med Verfahren zum transport von molekülen in eukaryotenzellen
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0511285A4 (en) * 1990-01-18 1993-05-26 Us Commerce Vector with multiple target response elements affecting gene expression
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
JPH06501938A (ja) * 1990-10-24 1994-03-03 アレリックス　バイオファーマシューティカルズ　アイエヌシー． ペプチドよりなるｈｉｖ複製阻害剤
JPH06508603A (ja) * 1991-02-14 1994-09-29 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション ＨＩＶ　Ｔａｔタンパク質に対する新規インテグリン特異性
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
EP0570357B1 (de) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
EP0642582A1 (de) * 1992-05-22 1995-03-15 Dana Farber Cancer Institute Hybride siv/hiv-1 virale vektoren und ein affenmodell für aids
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5421412A (en) * 1994-03-10 1995-06-06 North Carolina State University Methods and compositions for fracturing subterranean formations
EP0767678A1 (de) * 1994-05-23 1997-04-16 Gideon Goldstein Kompositionen zur transaktivierung von proteinen als humanen immunschwächevirus
US5793559A (en) * 1996-02-27 1998-08-11 Quantum Corporation In drive correction of servo pattern errors
SG52990A1 (en) * 1996-07-09 1998-09-28 Ibm Improvements to radial self-propagation pattern generation for disk file servowriting
US5875064A (en) * 1996-07-09 1999-02-23 International Business Machines Corporation Method and system for accurate self-servowriting with normalization in a disk drive
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6023145A (en) * 1999-04-21 2000-02-08 Guzik Technical Enterprises Head and disk tester with a thermal drift-compensated closed-loop positioning system
US6507450B1 (en) * 1999-06-11 2003-01-14 Western Digital Technologies, Inc. Method of continuously recording servo bursts along one continuous, single helix spiral
US6519107B1 (en) * 1999-09-24 2003-02-11 Maxtor Corporation Hard disk drive having self-written servo burst patterns
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CN101213212A (zh) * 2005-02-15 2008-07-02 西蒙有限公司 削弱hiv-1增殖的方法和组合物

Also Published As

Publication number Publication date
ES2317668T3 (es) 2009-04-16
ATE413189T1 (de) 2008-11-15
US20030194408A1 (en) 2003-10-16
US20030166832A1 (en) 2003-09-04
US7008622B2 (en) 2006-03-07
EP0994724B1 (de) 2008-11-05
CA2295691A1 (en) 1999-01-21
CA2295691C (en) 2012-01-24
US6193981B1 (en) 2001-02-27
US20060258594A1 (en) 2006-11-16
US6525179B1 (en) 2003-02-25
WO1999002185A1 (en) 1999-01-21
AU745012B2 (en) 2002-03-07
JP4278293B2 (ja) 2009-06-10
AU745012C (en) 2003-08-07
US5891994A (en) 1999-04-06
JP2001509368A (ja) 2001-07-24
EP0994724A4 (de) 2004-12-08
EP0994724A1 (de) 2000-04-26
AU8392798A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
ATE216225T1 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch- proteinen und nukleinsäuren
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
DK601786A (da) Hidtil ukendte prokoagulationsproteiner
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
ATE189684T1 (de) Rekombinante polypeptide und peptide, dafür kodierende nukleinsäuren und ihre verwendung in der tuberkulose-diagnose
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DK0426314T3 (da) HIV-relaterede peptider
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
EP0832109A4 (de) Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition